HK1092711A1 - Pharmeceutical composition with improved solubility and fluidity - Google Patents
Pharmeceutical composition with improved solubility and fluidityInfo
- Publication number
- HK1092711A1 HK1092711A1 HK06113473A HK06113473A HK1092711A1 HK 1092711 A1 HK1092711 A1 HK 1092711A1 HK 06113473 A HK06113473 A HK 06113473A HK 06113473 A HK06113473 A HK 06113473A HK 1092711 A1 HK1092711 A1 HK 1092711A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fluidity
- improved solubility
- pharmeceutical
- composition
- pharmeceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003313853A JP4575654B2 (en) | 2003-09-05 | 2003-09-05 | Pharmaceutical composition with improved solubility and fluidity |
PCT/JP2004/012827 WO2005023222A1 (en) | 2003-09-05 | 2004-09-03 | Pharmaceutical composition with improved solubility and fluidity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1092711A1 true HK1092711A1 (en) | 2007-02-16 |
Family
ID=34269778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06113473A HK1092711A1 (en) | 2003-09-05 | 2006-12-07 | Pharmeceutical composition with improved solubility and fluidity |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP4575654B2 (en) |
KR (1) | KR20060119860A (en) |
CN (1) | CN100389750C (en) |
HK (1) | HK1092711A1 (en) |
TW (1) | TWI344376B (en) |
WO (1) | WO2005023222A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1898951B1 (en) * | 2005-06-27 | 2013-02-27 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
US9102915B2 (en) * | 2006-11-13 | 2015-08-11 | DePuy Synthes Products, Inc. | In vitro expansion of postpartum-derived cells using microcarriers |
JP5201819B2 (en) * | 2006-11-22 | 2013-06-05 | エスエス製薬株式会社 | Solid composition |
JP5817715B2 (en) * | 2010-03-03 | 2015-11-18 | ライオン株式会社 | Solid pharmaceutical composition, pharmaceutical preparation and method for producing solid pharmaceutical composition |
CN105343006B (en) * | 2015-12-02 | 2019-05-14 | 北京大学 | A kind of nanometer shell system and its preparation method and application carrying insoluble drug |
CN105832680B (en) * | 2016-05-12 | 2018-12-25 | 沈阳药科大学 | A kind of pharmaceutical composition improving spirolactone In Vitro Dissolution and mobility |
JP6918392B2 (en) * | 2021-01-13 | 2021-08-11 | 築野食品工業株式会社 | Yield improvement in powder production or generation, scattering or solidification inhibitor of fine powder in powder use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU84875A1 (en) * | 1983-06-27 | 1985-03-29 | Oreal | TINCTORIAL COMPOSITIONS FOR KERATINIC FIBERS BASED ON DIRECT DYES AND XANTHANE GUM |
DE3720757A1 (en) * | 1987-06-24 | 1989-01-05 | Bayer Ag | DHP COAT TABLET |
CH675537A5 (en) * | 1988-03-25 | 1990-10-15 | Ciba Geigy Ag | |
JP3037393B2 (en) * | 1990-10-22 | 2000-04-24 | 大正薬品工業株式会社 | Method for producing solid drug for oral administration |
JP3302361B2 (en) * | 1990-11-30 | 2002-07-15 | 山之内製薬株式会社 | Immediate release coating formulation |
US5651983A (en) * | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
JP3247511B2 (en) * | 1993-09-07 | 2002-01-15 | 山之内製薬株式会社 | Pharmaceutical composition |
JP3096666B2 (en) * | 1996-11-01 | 2000-10-10 | 藤崎電機株式会社 | Method and apparatus for granulating powder |
JP3870470B2 (en) * | 1997-02-07 | 2007-01-17 | 大正製薬株式会社 | Multiple unit type sustained release tablets |
DE19709663A1 (en) * | 1997-03-10 | 1998-09-17 | Basf Ag | Use of redispersible polymer powders or polymer granules as binders for the production of solid pharmaceutical dosage forms |
JP4063386B2 (en) * | 1998-01-29 | 2008-03-19 | キッセイ薬品工業株式会社 | Rapid-release oral pharmaceutical composition |
JP4438121B2 (en) * | 1998-04-27 | 2010-03-24 | 大正製薬株式会社 | Intraoral rapidly disintegrating tablet and method for producing the same |
GB9816899D0 (en) * | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
CA2374760A1 (en) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Quickly disintegrating solid preparations |
-
2003
- 2003-09-05 JP JP2003313853A patent/JP4575654B2/en not_active Expired - Lifetime
-
2004
- 2004-09-03 WO PCT/JP2004/012827 patent/WO2005023222A1/en active Application Filing
- 2004-09-03 CN CNB2004800245287A patent/CN100389750C/en not_active Expired - Fee Related
- 2004-09-03 TW TW093126705A patent/TWI344376B/en not_active IP Right Cessation
- 2004-09-03 KR KR1020067002247A patent/KR20060119860A/en not_active Application Discontinuation
-
2006
- 2006-12-07 HK HK06113473A patent/HK1092711A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP4575654B2 (en) | 2010-11-04 |
CN100389750C (en) | 2008-05-28 |
TW200514571A (en) | 2005-05-01 |
KR20060119860A (en) | 2006-11-24 |
JP2005082503A (en) | 2005-03-31 |
WO2005023222A1 (en) | 2005-03-17 |
TWI344376B (en) | 2011-07-01 |
CN1842324A (en) | 2006-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2089A (en) | Compositions and methods for combination antiviraltherapy | |
HK1080717A1 (en) | Pharmaceutical compositions with improved dissolution | |
EP1654005A4 (en) | Stable radiopharmaceutical compositions and methods for preparation | |
GB0411940D0 (en) | Methods and compositions | |
IL173639A (en) | Ppar-activating compound and pharmaceutical composition containing same | |
EP1701725A4 (en) | Methods and compositions | |
IL197889A (en) | Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same | |
HU0301154D0 (en) | Pharmaceutical composition | |
IL183986A0 (en) | Pharmaceutical compounds and compositions | |
IL182126A (en) | Compositions containing 5-phenoxyalkoxypsoralen derivatives and uses thereof | |
GB0300427D0 (en) | Pharmaceutical composition | |
HK1092711A1 (en) | Pharmeceutical composition with improved solubility and fluidity | |
GB0307866D0 (en) | Pharmaceutical composition | |
EP1699458A4 (en) | Pharmaceutical composition | |
GB0329232D0 (en) | Pharmaceutical composition | |
GB0317663D0 (en) | Pharmaceutical composition | |
HK1093896A1 (en) | Medicinal composition | |
AU2003267231A8 (en) | Pharmaceutical compositions with improved dissolution | |
EP1600445A4 (en) | Medicinal composition | |
GB0300885D0 (en) | Pharmaceutical composition | |
EP1655029A4 (en) | Medicinal compositions | |
HK1095737A1 (en) | Medicinal composition in solution form | |
GB0306933D0 (en) | Pharmaceutical composition | |
GB0307869D0 (en) | Pharmaceutical composition | |
GB0307862D0 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130903 |